Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Fish-rich and vegetarian diet may reduce hypertension-related heart disease symptoms

Elevated levels of trimethylamine N-oxide--a compound linked with the consumption of fish, seafood and a primarily vegetarian diet--may reduce hypertension-related heart disease symptoms.

7 Nov 2018

Insilico Medicine to present latest advances in drug development at Supply Side West Conference

Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest advances in modern drug development at the Supply Side West Conference in Las Vegas, 8-9 of November.

2 Nov 2018

UA professor wins NIH grant to advance research in preventing heart failure

A University of Arizona College of Medicine - Phoenix researcher has received a $393,493 grant from the National Institutes of Health to further her research in reducing the risk of heart failure in patients with high blood pressure.

1 Nov 2018

Insilico to present its research in AI for drug discovery at BioCentury China HealthCare Summit

Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its research in AI for drug discovery at BioCentury China HealthCare Summit in Shanghai, 13-14 of November.

31 Oct 2018

Insilico to present latest research on biomarkers at Investing in the Age of Longevity Conference

Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest advances in human aging biomarker development at the Investing in the Age of Longevity Conference in London, 1 of November.

30 Oct 2018

Novartis enters into clinical development agreement with Pfizer to improve treatment of NASH

Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).

29 Oct 2018

Toxic effects of drugs in the lungs 'more widespread than thought'

A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought.

29 Oct 2018

Researchers identify new potential target to inhibit progression of liver disease

Naglaa Shoukry, Ph. D., and her team have made a significant breakthrough in their research aiming to limit the progression of liver disease.

26 Oct 2018

Bioengineering scientists propose new paradigm for research into cardiovascular diseases

Thrombosis-on-a-chip, vasculature-on-a-chip and engineered models of human cardiac fibrosis are just a few of the new technologies revolutionizing research into human cardiovascular disease--a condition responsible for 17 million deaths per annum globally.

25 Oct 2018

Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC

Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, today announced that the first patient has been dosed in a Phase 2a trial evaluating the efficacy and safety of AVID100 in patients with squamous non-small cell lung cancer whose tumors overexpress epidermal growth factor receptor.

23 Oct 2018

Researchers identify common genetic connection in lung conditions

An international research team led by members of the University of Colorado School of Medicine faculty has identified a genetic connection between rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis.

22 Oct 2018

Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for KALYDECO (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

22 Oct 2018

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.

22 Oct 2018

Synspira’s abstracts accepted for presentation at the 32nd Annual NACFC

Synspira, a privately held company developing a new class of inhaled glycopolymer-based therapeutics for the treatment of pulmonary disease, today announced that three abstracts have been accepted for presentation at the 32nd Annual North American Cystic Fibrosis Conference, occurring October 18-20 in Denver, CO.

12 Oct 2018

Mast cells associated with allergies also play key role in survival, study reveals

In a University of California, Irvine-led study, researchers found evidence that mast cells, an important group of immune cells typically associated with allergies, actually enable the body to survive fasting or intense exercise.

12 Oct 2018

Insilico to present advances in artificial intelligence at the Healthcare Innovation Summit Africa 2018

Insilico Medicine, a Rockville-based leader in next-generation artificial intelligence for drug discovery, biomarker development, and aging research, is pleased to announce the talk of its Head of Africa Artificial Intelligence for Healthcare Initiative, Iraneus Ogu, who will present alongside other academic thought leaders and industry experts at the 4th Healthcare Innovation Summit Africa 2018, one of the largest healthcare events in Africa.

12 Oct 2018

Top journal publishes special issue on deep learning for drug discovery and biomarker development

While the many concepts in artificial intelligence date back to the 20th century, the revolution in deep learning started around 2014-2015 when AI systems started outperforming humans in many tasks ranging from video games and image recognition to autonomous driving.

11 Oct 2018

Synedgen announces market launch of Moisyn Rinse for treatment of dry mouth symptoms

Synedgen, a company leveraging its proprietary glycomics technology platform to develop glycopolymer-based therapeutics for infectious and inflammatory conditions, today announced the market launch of Moisyn Rinse for the treatment of the symptoms of xerostomia, or dry mouth. Moisyn Rinse is being distributed by Prisyna, the oral care division of Synedgen.

10 Oct 2018

Veracyte to present data demonstrating potential of Envisia Genomic Classifier to improve ILD diagnosis

Veracyte, Inc. announced the presentation of data demonstrating that the Envisia Genomic Classifier can help physicians more confidently diagnose interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), without the need for surgery.

8 Oct 2018

Gram-negative bacteria found to be risk factor for worse outcomes in hospitalized ILD patients

Alterations to the respiratory microbiome have been identified as a predisposing factor of interstitial lung diseases. In a study at CHEST 2018, researchers at Beaumont Health Systems studied the influence of bacterial virulence on clinical outcomes patients hospitalized with ILD patients.

4 Oct 2018

Fibrosis News and Research

Further Reading

Fish-rich and vegetarian diet may reduce hypertension-related heart disease symptoms

Insilico Medicine to present latest advances in drug development at Supply Side West Conference

UA professor wins NIH grant to advance research in preventing heart failure

Insilico to present its research in AI for drug discovery at BioCentury China HealthCare Summit

Insilico to present latest research on biomarkers at Investing in the Age of Longevity Conference

Novartis enters into clinical development agreement with Pfizer to improve treatment of NASH

Toxic effects of drugs in the lungs 'more widespread than thought'

Researchers identify new potential target to inhibit progression of liver disease

Bioengineering scientists propose new paradigm for research into cardiovascular diseases

Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC

Researchers identify common genetic connection in lung conditions

Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Synspira’s abstracts accepted for presentation at the 32nd Annual NACFC

Mast cells associated with allergies also play key role in survival, study reveals

Insilico to present advances in artificial intelligence at the Healthcare Innovation Summit Africa 2018

Top journal publishes special issue on deep learning for drug discovery and biomarker development

Synedgen announces market launch of Moisyn Rinse for treatment of dry mouth symptoms

Veracyte to present data demonstrating potential of Envisia Genomic Classifier to improve ILD diagnosis

Gram-negative bacteria found to be risk factor for worse outcomes in hospitalized ILD patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News